Anna Thomas is a prominent inventor based in Freiburg, Germany. She has made significant contributions to the field of immunology, particularly in the activation and expansion of T-cells. With a total of 4 patents, her work is paving the way for advancements in research tools and therapeutic applications.

Latest Patents

One of her latest patents focuses on the activation and expansion of T-cells using an engineered multivalent signaling platform as a research tool. This innovative system allows for the selective induction of T-cell expansion without the need for exogenous growth factors, such as lymphokines, and accessory cells. The methods provided enable the long-term growth of cytotoxic T lymphocytes (CTLs), particularly human CTLs. Furthermore, T-cell proliferation can be induced without requiring antigen, resulting in a polyclonal T-cell population with respect to antigen reactivity. This technology also includes methods for screening and identifying antigens related to various diseases, tumors, autoimmune disorders, and infectious pathogens, which can aid in the development of targeted vaccines.

Career Highlights

Anna Thomas is affiliated with the University of Pennsylvania, where she continues her research and development efforts. Her work has garnered attention for its potential impact on immunotherapy and vaccine development.

Collaborations

Some of her notable coworkers include Marcela V Maus and James L Riley, who contribute to the collaborative efforts in advancing T-cell research.

Conclusion

Anna Thomas is a key figure in the field of T-cell research, with her innovative patents and collaborative work promising to enhance our understanding and treatment of various diseases. Her contributions are vital for the future of immunological research and therapeutic development.

Profile summary based on public USPTO records.

Please report any incorrect information to [email protected]